You are here:

rosuvastatin (Crestor®)


Recommended for general use within NHS Scotland.
Indication Under Review:

primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet, when response to diet and exercise is inadequate.

homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid-lowering treatments (e.g. LDL apheresis).
Rosuvastatin is a new HMG-CoA reductase inhibitor, with costs and efficacy in reducing low-density-lipoprotein-cholesterol (LDL-C) comparable to other statins.  Its current licenced indications are more limited than some other statins.

Drug Details

Drug Name: rosuvastatin (Crestor®)
SMC Drug ID: 45/03
Manufacturer: AstraZeneca UK Ltd
Indication: Primary hypercholesterolaemia or mixed dyslipidaemia
BNF Category:
Sub Category: 2.12 Lipid-regulating drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 May 2003